(From the March 2014 Issue of MedStat)
For more detailed information, contact Kimberly Novak at Kimberly.Novak@NationwideChildren.org.
Medication Stock Lists were APPROVED for the following clinics: Pediatric Surgery, Eating Disorders Program, Primary Care Red, and Primary Care Yellow.
Dermatology Clinic Sample Requests were APPROVED for the following items: Aurstat (emollient cream) and Aczone Gel (dapsone).
The Pyxis Override List was APPROVED for H09B.
Criteria for Default Designation of Long-term Medications in Epic were APPROVED. Medications must meet BOTH of the following criteria to be defaulted as a long-term medication on home medication lists: 1.) Interruption of medication therapy is likely to be rapidly detrimental to the patient, AND 2.) Medication therapy is typically intended for longer than 30 days duration for the majority of patients for whom it is prescribed.
A Ketamine for Analgesia Protocol for management by the Pain and Palliative Care Medicine Teams was APPROVED for a 3 month trial period or until at least 5 patients have been treated. A Pain or Palliative Care Medicine practitioner will be required to be present at ketamine initiation to facilitate protocol implementation during this period. Education will be conducted in March and April with full roll-out planned for May 2014. An audit of clinical outcomes and safety will be presented by the Pain and Palliative Care Medicine to P&T after the trial period for determination of more long-term approval. Order sets and drug card updates/Lexi-Comp customization are currently in development.
The Factor VIII Recombinant-Investigational Drug Card was APPROVED.
An Audit of Endocrinology Consults was presented by Dr. Repaske for informational purposes. Consults are reviewed weekly by a QI team for adherence to the Endocrinology Consult Policy for admitting services. Adherence has been improving with 2 of the last 8 months having 100% adherence. Greater than 90% of consults are responded to within 24 hours.
An update on resident prescribing restrictions for monoclonal antibodies was presented by Karl Kappeler for informational purposes. Implementation of second-sign workflow within Epic will be pursued to facilitate this process.